ESMO® 2026 Highlights: Presenter Vignettes – Kevin Kalinsky

Dr. Kevin Kalinsky

Kevin Kalinsky

MD, MS, FASCO

Emory University School of Medicine

1RO

Overall survival from the Phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy